AZT

AZTherapies is a clinical-stage biopharmaceutical company focused on developing novel therapies for neurodegenerative diseases, with a primary emphasis on Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The company's lead program, ALZT-OP1, is a combination therapy designed to inhibit amyloid-beta aggregation and suppress neuroinflammation by shifting microglia from a pro-inflammatory to a neuroprotective state. AZTherapies utilizes a multi-modal approach to address the complex pathophysiology of brain disorders, aiming to slow or halt disease progression rather than just treating symptoms. Headquartered in Boston, the company is advancing a pipeline that includes treatments for post-ischemic stroke cognitive impairment and other neuroinflammatory conditions.